Esperion Therapeutics (LTS:0IIM) Total Assets : $343.8 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics Total Assets?

Esperion Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $343.8 Mil.

During the past 12 months, Esperion Therapeutics's average Total Assets Growth Rate was 61.10% per year. During the past 3 years, the average Total Assets Growth Rate was 17.60% per year. During the past 5 years, the average Total Assets Growth Rate was 57.10% per year. During the past 10 years, the average Total Assets Growth Rate was 15.00% per year.

During the past 13 years, Esperion Therapeutics's highest 3-Year average Total Assets Growth Rate was 370.50%. The lowest was -57.00%. And the median was 27.50%.

Total Assets is connected with ROA %. Esperion Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -25.92%. Total Assets is also linked to Revenue through Asset Turnover. Esperion Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.21.

Esperion Therapeutics Total Assets Historical Data

The historical data trend for Esperion Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Total Assets Chart

Esperion Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

353.26

381.59

247.94

205.80

343.82

Esperion Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															205.80	373.06	352.32	314.11	343.82

Esperion Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Esperion Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	-388.722	+	732.543
	=	343.8

Esperion Therapeutics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	-388.722	+	732.543
	=	343.8

Esperion Therapeutics (LTS:0IIM) Total Assets Explanation

Total Assets is connected with ROA %.

Esperion Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-85.272	/	( (314.114	+	343.821)	/ 2 )
	=	-85.272	/	328.9675
	=	-25.92 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Esperion Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	69.113	/	( (314.114	+	343.821)	/ 2 )
=	69.113	/	328.9675
=	0.21

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Esperion Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Esperion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ESPR:USA 0ET:Germany 0ET:Germany

Address

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108

Website

https://www.esperion.com

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines